GT Biopharma (NASDAQ:GTBP) Stock Price Down 8.8% – What’s Next?

GT Biopharma, Inc. (NASDAQ:GTBP)’s stock price was down 8.8% during trading on Monday . The stock traded as low as $0.3730 and last traded at $0.3877. Approximately 1,719,132 shares changed hands during mid-day trading, an increase of 45% from the average session volume of 1,181,820 shares. The stock had previously closed at $0.4250.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, GT Biopharma presently has an average rating of “Sell”.

GT Biopharma Stock Down 8.8%

The firm has a market capitalization of $17.19 million, a P/E ratio of -0.06 and a beta of 0.84. The business’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.49.

GT Biopharma (NASDAQ:GTBP) last announced its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). As a group, equities analysts anticipate that GT Biopharma, Inc. will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. SeaCrest Wealth Management LLC bought a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned approximately 0.47% of GT Biopharma at the end of the most recent reporting period. 8.15% of the stock is currently owned by institutional investors.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).